1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Results of functional and electrophysiologic evaluation (mean ± SEM)
4 Weeks8 Weeks
SFIa
    NGF−79.98 ± 4.58−64.65 ± 4.11
    EPO−78.85 ± 3.87, P > .05−60.26 ± 2.91, P < .05
MNCV (m/s)b
    NGF9.20 ± 1.0716.37 ± 3.40
    EPO10.60 ± 1.36, P < .0520.56 ± 4.18, P < .05
  • a The SFI studies at 8 weeks postsurgery demonstrated better improvement in nerve function in rats that received EPO.
  • b Rats treated with EPO showed better results than those of the NGF group at the 2 time points.